Sanofi gives notice it is termination deal with Oxford Biomedica

19 March 2021

UK-based Oxford Biomedica (LSE: OXB), a gene and cell therapy group, announced today that French pharma major Sanofi (Euronext: SAN) has given notice that it intends to terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat hemophilia.

News of the decision, made via a notification to the London Stock Exchange, pushed the UK firm’s shares down almost 6% to 961.95 pence by mid-afternoon trading today.

Oxford Biomedica had originally signed the $100 million collaboration and license agreement with Bioverativ, which was acquired by Sanofi in February 2018 in an $11.6 billion deal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK